Publications by authors named "Diepstraten F"
Introduction: Ototoxicity is an adverse effect of childhood cancer treatment with a negative impact on speech-language development and quality of life. This study aimed to retrospectively assess ototoxicity monitoring in a national cohort of pediatric patients with solid tumors, examining the frequency and determinants associated with hearing loss (HL).
Methods: This retrospective cohort study included 305 patients treated between 2015 and 2020 at the Princess Máxima Center.
Article Synopsis
- Hearing loss affects 50-70% of children receiving cisplatin treatment, but a pediatric formula of intravenous sodium thiosulfate (STS) has been approved for its protection by major health agencies.
- A review of 31 studies indicates that systemic STS can effectively reduce cisplatin-induced hearing loss (CIHL) in both children and adults, with its effectiveness depending on the timing and dosage of STS relative to cisplatin administration.
- Although STS reduces CIHL, further research is necessary to better understand the pharmacokinetics of STS with cisplatin, its effects on patients with widespread disease, and its capability to stop the worsening of existing hearing loss.
Ototoxicity is a devastating direct, irreversible side effect of platinum use in children with cancer, with its consequent effect on speech, language and social development, quality of life and adult productivity. Cisplatin, an essential chemotherapeutic agent for the treatment of solid tumors in children, is a DNA cross-linking agent. Which causes hearing loss in 50-70% of cisplatin treated children.
View Article and Find Full Text PDFPurpose: The frequency and patterns of HL in a HNRMS survivor cohort were investigated. A dose-effect relationship between the dose to the cochlea and HL was explored.
Methods: Dutch survivors treated for HNRMS between 1993 and 2017 with no relapse and at least two years after the end of treatment were eligible for inclusion.
Article Synopsis
- * The study involves a national cohort of children aged 0 to 19 years, who will undergo audiological testing before and after treatment, assessing not only hearing loss but also tinnitus and vertigo.
- * By evaluating the independent effects of comedications like antibiotics and diuretics on ototoxicity, the research seeks to enhance understanding and management of hearing-related complications in childhood cancer patients.
Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review.
JAC Antimicrob Resist
December 2021
Background: Ototoxicity has been reported after administration of aminoglycosides and glycopeptides.
Objectives: To identify available evidence for the occurrence and determinants of aminoglycoside- and glycopeptide-related ototoxicity in children.
Materials And Methods: Systematic electronic literature searches that combined ototoxicity (hearing loss, tinnitus and/or vertigo) with intravenous aminoglycoside and/or glycopeptide administration in children were performed in PubMed, EMBASE and Cochrane Library databases.
In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss in 390 non-cranial irradiated, cisplatin-treated children with cancer. These results were replicated in two independent, similarly treated cohorts (n = 192 and 188, respectively) (combined cohort: P = 5.
View Article and Find Full Text PDF